The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients ...
In men with localized, intermediate-risk prostate cancer, stereotactic body radiation therapy (SBRT) was associated with less toxicity at 2 years but a higher rate of biochemical failure at 3 years ...
A groundbreaking new study suggests that prostate cancer treatment may soon become faster, simpler, and less disruptive for ...
A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...
Secret Life of Mom on MSN
Easier way to treat prostate cancer could become new 'standard of care,' doctors say
Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results